Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Article in English | MEDLINE | ID: mdl-38363431

ABSTRACT

BACKGROUND: Early recurrence (ER) within a 90-day blanking period (BP) in catheter ablation (CA) for atrial fibrillation (AF) is a risk factor for late recurrence (LR) after 90 days postoperatively. However, few reports have examined them in the second CA and compared them to the first CA. Moreover, in recent years, there have been reports suggesting that BP should be reduced from 90 to 30 days. Therefore, the association between ER and LR in the first and the second CA was examined, and the validity of a 30-day BP was evaluated. METHODS: A total of 511 consecutive patients undergoing the first CA and 116 of these patients undergoing the second CA for AF at a single institution from November 2016 to December 2020 were analyzed retrospectively. RESULTS: When ER within a 90-day BP was divided into 0-30 days and 31-90 days according to the timing of the last ER episode, the hazard ratios on LR of them relative to no ER were 2.7 {95% confidence interval (CI) 1.7-4.2} and 9.7 (95% CI 6.6-14.3), respectively, for the first CA and 15.3 (95% CI 4.7-50.1) and 44.1 (95% CI 14.0-139.4), respectively, for the second CA. CONCLUSIONS: ER was strongly associated with LR, especially in patients with the last episode of ER more than 30 days after CA. This was pronounced in cases after the second CA, when PVI appeared to be completed. With the current improvement in PVI durability, BP may be acceptable for 30 days.

2.
J Cardiol Cases ; 27(5): 229-232, 2023 May.
Article in English | MEDLINE | ID: mdl-36779079

ABSTRACT

A 71-year-old man was transferred urgently to our hospital after collapsing near his home post the first shot of the BNT162b2 coronavirus disease 2019 vaccine (Pfizer-BioNTech, Comirnaty®). Immediately after arrival at our hospital, cardiac arrest due to complete atrioventricular block with no ventricular escaped beats was observed on electrocardiogram. Echocardiography showed preserved left ventricular ejection fraction, however, diffuse severe hypokinesia was revealed after 3 weeks, and he died 3 months after admission because of worsening heart failure. An autopsy examination revealed eosinophilic myocarditis or hypersensitivity myocarditis with extensive fibrosis and widespread myocardial dropout throughout the heart. Learning objective: 1. Severe myocarditis occurs extremely rarely after mRNA coronavirus disease 2019 (COVID-19) vaccination. 2. Myocarditis after mRNA COVID-19 vaccination might cause complete atrioventricular block, followed by a course of decreased left ventricular ejection fraction. 3. Histologically, severe myocarditis after mRNA COVID-19 vaccination seems to present as fulminant necrotizing eosinophilic myocarditis or hypersensitivity myocarditis.

3.
J Arrhythm ; 36(6): 1096-1099, 2020 Dec.
Article in English | MEDLINE | ID: mdl-33335631

ABSTRACT

A 77-year-old woman with symptomatic paroxysmal atrial fibrillation (PAF) underwent pulmonary vein isolation (PVI), but subsequently experienced recurrence. In the second session, unidirectional left atrium (LA)-left superior pulmonary vein (LSPV) conduction was revealed to exist at the carina of the LSPV. Left pulmonary vein (LPV) pacing performed in a cycle between 300 and 260 ms revealed rate-dependent pulmonary vein (PV)-LA conduction, and the location was estimated to be in the roof of the LSPV. PV isolation was achieved after ablation of two gaps. Consideration of the presence of rate-dependent gaps may be useful to confirm bidirectional block lines after ablation.

4.
Catheter Cardiovasc Interv ; 96(6): 1174-1181, 2020 11.
Article in English | MEDLINE | ID: mdl-31802610

ABSTRACT

OBJECTIVES: We analyzed the effect of high flow-volume intermittent hemodiafiltration (HF-IHDF) on patients with advanced chronic kidney disease (CKD) undergoing procedures requiring administration of contrast medium. BACKGROUND: There is no effective method for preventing contrast-induced nephropathy (CIN), especially in patients with advanced CKD. We established HF-IHDF as a renal protective therapy with a filtration flow rate up to 5 times greater than standard continuous HDF. In this study, we tested whether HF-IHDF could prevent CIN in patients with advanced CKD more effectively than saline hydration only. METHODS: We retrospectively analyzed the incidence of CIN and clinical outcomes up to 1 year after performance of a procedure in 76 patients with advanced CKD. HF-IHDF was performed from just before the procedure until 2.5 hr after it. Hydration with 0.9% saline was also administered. RESULTS: The incidence of CIN was significantly lower in the HF-IHDF group than the saline group 2-3 days (0%, 0/76 patients vs. 9.3%, 5/54 patients; p < .05) and 1 month (3.9%, 3/76 patients vs. 14.8%, 8/54 patients; p < .05) after intervention. No difference between the two groups was detected in the proportion of patients requiring permanent hemodialysis within 1 year after intervention or the 1 year mortality rate. However, the number of patients free from progression of renal dysfunction after 1 year of follow-up was significantly higher in the HF-IHDF group (86.8%, 66/76 patients vs. 64.8%, 35/54 patients; p < .01). CONCLUSIONS: HF-IHDF during and after interventional procedure requiring administration of contrast medium may prevent CIN in patients with advanced CKD.


Subject(s)
Acute Kidney Injury/prevention & control , Contrast Media/adverse effects , Intermittent Renal Replacement Therapy , Renal Insufficiency, Chronic/complications , Acute Kidney Injury/chemically induced , Acute Kidney Injury/diagnosis , Aged , Aged, 80 and over , Contrast Media/administration & dosage , Female , Humans , Intermittent Renal Replacement Therapy/adverse effects , Male , Pilot Projects , Renal Insufficiency, Chronic/diagnosis , Retrospective Studies , Risk Assessment , Risk Factors , Time Factors , Treatment Outcome
5.
J Clin Endocrinol Metab ; 96(9): 2771-8, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21752891

ABSTRACT

CONTEXT: Adrenal venous sampling is the "gold standard" test in the diagnosis of an aldosterone-producing adenoma (APA) among patients with primary aldosteronism (PA) but is available only in specialized medical centers. Meanwhile, an APA is reported to be generally more sensitive to ACTH than idiopathic hyperaldosteronism. OBJECTIVE: The aim was to evaluate the diagnostic accuracy of the ACTH stimulation test in the diagnosis of an APA among those with suspicion of PA. PATIENTS AND SETTING: Fifty-nine patients admitted to Kyoto University Hospital on suspicion of PA were included in the study. INTERVENTIONS: ACTH stimulation tests with 1-mg dexamethasone suppression were performed. MAIN OUTCOME MEASURE: Plasma aldosterone concentrations (PAC) were examined every 30 min after ACTH stimulation. Receiver-operated characteristics curve analysis was used to evaluate the diagnostic accuracy. RESULTS: PAC after ACTH stimulations were significantly higher in patients with an APA than in patients with idiopathic hyperaldosteronism or non-PA. Receiver-operated characteristics curve analyses showed that the PAC after ACTH stimulation was effective for the diagnosis of an APA among patients suspected of PA. The diagnostic accuracy was highest at 90 min after ACTH injection, with the optimal cutoff value greater than 37.9 ng/dl corresponding with sensitivity and specificity of 91.3 and 80.6% for the diagnosis of an APA. CONCLUSIONS: Our study indicates that the ACTH stimulation test is useful in the diagnosis of an APA among patients suspected of PA. This test can be used to select patients who are highly suspected of an APA and definitely require adrenal venous sampling.


Subject(s)
Adenoma/diagnosis , Adrenal Cortex Neoplasms/diagnosis , Adrenocorticotropic Hormone , Aldosterone/metabolism , Hyperaldosteronism/diagnosis , Adenoma/blood , Adenoma/metabolism , Adrenal Cortex Neoplasms/blood , Adrenal Cortex Neoplasms/metabolism , Aldosterone/blood , Dexamethasone , Female , Humans , Hyperaldosteronism/blood , Male , Middle Aged
6.
Endocrinology ; 151(8): 3633-42, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20555027

ABSTRACT

The physiological implication of C-type natriuretic peptide (CNP) including energy metabolism has not been elucidated, because of markedly short stature in CNP-null mice. In the present study we analyzed food intake and energy expenditure of CNP-null mice with chondrocyte-targeted CNP expression (CNP-Tg/Nppc(-/-) mice), in which marked skeletal dysplasia was rescued, to investigate the significance of CNP under minimal influences of skeletal phenotypes. In CNP-Tg/Nppc(-/-) mice, body weight and body fat ratio were reduced by 24% and 32%, respectively, at 20 wk of age, and decreases of blood glucose levels during insulin tolerance tests were 2-fold exaggerated at 17 wk of age, as compared with CNP-Tg/Nppc(+/+) mice. Urinary noradrenalin excretion of CNP-Tg/Nppc(-/-) mice was greater than that of CNP-Tg/Nppc(+/+) mice by 28%. In CNP-Tg/Nppc(-/-) mice, rectal temperature at 1600 h was higher by 1.1 C, and uncoupling protein-1 mRNA expression in the brown adipose tissue was 2-fold increased, which was canceled by propranolol administration, as compared with CNP-Tg/Nppc(+/+) mice. Oxygen consumption was significantly increased in CNP-Tg/Nppc(-/-) mice compared with that in CNP-Tg/Nppc(+/+) mice. Food intake of CNP-Tg/Nppc(-/-) mice upon ad libitum feeding and refeeding after 48 h starvation were reduced by 21% and 61%, respectively, as compared with CNP-Tg/Nppc(+/+) mice. This study unveiled a new aspect of CNP as a molecule regulating food intake and energy expenditure. Further analyses on precise mechanisms of CNP actions would lead to the better understanding of the significance of the CNP/guanylyl cyclase-B system in food intake and energy expenditure.


Subject(s)
Appetite Regulation/genetics , Energy Metabolism/genetics , Natriuretic Peptide, C-Type/physiology , Agouti-Related Protein/genetics , Agouti-Related Protein/metabolism , Animals , Appetite Regulation/drug effects , Body Temperature/drug effects , Body Temperature/genetics , Chondrocytes/drug effects , Chondrocytes/metabolism , Energy Metabolism/drug effects , Gene Expression Regulation/drug effects , Guanylate Cyclase/genetics , Guanylate Cyclase/metabolism , Injections, Intraventricular , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Natriuretic Peptide, C-Type/administration & dosage , Natriuretic Peptide, C-Type/genetics , Natriuretic Peptide, C-Type/metabolism , Neuropeptide Y/genetics , Neuropeptide Y/metabolism , Norepinephrine/urine , Organ Specificity/genetics , PPAR gamma/genetics , PPAR gamma/metabolism , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha , Tissue Distribution , Trans-Activators/genetics , Trans-Activators/metabolism , Transcription Factors
7.
Arterioscler Thromb Vasc Biol ; 29(7): 1100-3, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19423866

ABSTRACT

OBJECTIVE: Induced pluripotent stem (iPS) cells are a novel stem cell population derived from human adult somatic cells through reprogramming using a defined set of transcription factors. Our aim was to determine the features of the directed differentiation of human iPS cells into vascular endothelial cells (ECs) and mural cells (MCs), and to compare that process with human embryonic stem (hES) cells. METHODS AND RESULTS: We previously established a system for differentiating hES cells into vascular cells. We applied this system to human iPS cells and examined their directed differentiation. After differentiation, TRA1-60(-) Flk1(+) cells emerged and divided into VE-cadherin-positive and -negative populations. The former were also positive for CD34, CD31, and eNOS and were consistent with ECs. The latter differentiated into MCs, which expressed smooth muscle alpha-actin and calponin after further differentiation. The efficiency of the differentiation was comparable to that of human ES cells. CONCLUSIONS: We succeeded in inducing and isolating human vascular cells from iPS cells and indicate that the properties of human iPS cell differentiation into vascular cells are nearly identical to those of hES cells. This work will contribute to our understanding of human vascular differentiation/development and to the development of vascular regenerative medicine.


Subject(s)
Cell Differentiation , Endothelial Cells/cytology , Pluripotent Stem Cells/cytology , Cell Line , Embryonic Stem Cells/cytology , Flow Cytometry , Humans
8.
FEBS Lett ; 583(12): 2067-70, 2009 Jun 18.
Article in English | MEDLINE | ID: mdl-19463821

ABSTRACT

Anti-fibrotic and organ protective effects of brain natriuretic peptide (BNP) have been reported. In this study, effects of BNP on liver fibrosis were examined in the carbon tetrachloride (CCl(4))-induced liver fibrosis model using BNP-transgenic (Tg) and wild-type (WT) mice. Twice-a-week intraperitoneal injections of CCl(4) for 8 weeks resulted in massive liver fibrosis, augmented transforming growth factor (TGF)-beta(1) and type I procollagen alpha(1) chain (Col1a1) mRNA expression, and the hepatic stellate cell (HSC) activation in WT mice, all of which were significantly suppressed in Tg mice. These observations indicate that BNP inhibits liver fibrosis by attenuating the activation of HSCs.


Subject(s)
Liver Cirrhosis, Experimental/prevention & control , Natriuretic Peptide, Brain/physiology , Animals , Carbon Tetrachloride/toxicity , Collagen Type I/genetics , Collagen Type I, alpha 1 Chain , Hepatic Stellate Cells/pathology , Hepatic Stellate Cells/physiology , Liver/pathology , Liver/physiopathology , Liver Cirrhosis, Experimental/chemically induced , Liver Cirrhosis, Experimental/genetics , Liver Cirrhosis, Experimental/pathology , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Natriuretic Peptide, Brain/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , Transforming Growth Factor beta1/genetics
9.
FEBS Lett ; 583(6): 1029-33, 2009 Mar 18.
Article in English | MEDLINE | ID: mdl-19250937

ABSTRACT

Induced pluripotent stem (iPS) cells were recently established from human fibroblasts. In the present study we investigated the adipogenic differentiation properties of four human iPS cell lines and compared them with those of two human embryonic stem (ES) cell lines. After 12 days of embryoid body formation and an additional 10 days of differentiation on Poly-l-ornithine and fibronectin- coated dishes with adipogenic differentiation medium, human iPS cells exhibited lipid accumulation and transcription of adipogenesis-related molecules such as C/EBPalpha, PPARgamma2, leptin and aP2. These results demonstrate that human iPS cells have an adipogenic potential comparable to human ES cells.


Subject(s)
Adipogenesis/physiology , Cell Differentiation/physiology , Embryonic Stem Cells/physiology , Pluripotent Stem Cells/physiology , Adipocytes/drug effects , Adipocytes/physiology , Adipogenesis/drug effects , Adipogenesis/genetics , Biomarkers/metabolism , CCAAT-Enhancer-Binding Proteins/genetics , CCAAT-Enhancer-Binding Proteins/metabolism , Cell Culture Techniques , Cell Differentiation/drug effects , Cell Differentiation/genetics , Cells, Cultured , Embryonic Stem Cells/drug effects , Embryonic Stem Cells/metabolism , Fatty Acid-Binding Proteins/genetics , Fatty Acid-Binding Proteins/metabolism , Fibronectins/pharmacology , Gene Expression , Homeodomain Proteins/genetics , Homeodomain Proteins/metabolism , Humans , Leptin/genetics , Leptin/metabolism , Nanog Homeobox Protein , PPAR gamma/genetics , PPAR gamma/metabolism , Peptides/pharmacology , Pluripotent Stem Cells/drug effects , Pluripotent Stem Cells/metabolism
10.
J Transl Med ; 6: 54, 2008 Sep 30.
Article in English | MEDLINE | ID: mdl-18823569

ABSTRACT

BACKGROUND: We previously demonstrated that vascular endothelial growth factor receptor type 2 (VEGF-R2)-positive cells induced from mouse embryonic stem (ES) cells can differentiate into both endothelial cells (ECs) and mural cells (MCs) and these vascular cells construct blood vessel structures in vitro. Recently, we have also established a method for the large-scale expansion of ECs and MCs derived from human ES cells. We examined the potential of vascular cells derived from human ES cells to contribute to vascular regeneration and to provide therapeutic benefit for the ischemic brain. METHODS: Phosphate buffered saline, human peripheral blood mononuclear cells (hMNCs), ECs-, MCs-, or the mixture of ECs and MCs derived from human ES cells were intra-arterially transplanted into mice after transient middle cerebral artery occlusion (MCAo). RESULTS: Transplanted ECs were successfully incorporated into host capillaries and MCs were distributed in the areas surrounding endothelial tubes. The cerebral blood flow and the vascular density in the ischemic striatum on day 28 after MCAo had significantly improved in ECs-, MCs- and ECs+MCs-transplanted mice compared to that of mice injected with saline or transplanted with hMNCs. Moreover, compared to saline-injected or hMNC-transplanted mice, significant reduction of the infarct volume and of apoptosis as well as acceleration of neurological recovery were observed on day 28 after MCAo in the cell mixture-transplanted mice. CONCLUSION: Transplantation of ECs and MCs derived from undifferentiated human ES cells have a potential to contribute to therapeutic vascular regeneration and consequently reduction of infarct area after stroke.


Subject(s)
Blood Cells/transplantation , Blood Vessels/physiology , Embryonic Stem Cells/transplantation , Regeneration , Stroke/physiopathology , Stroke/therapy , Angiogenesis Inducing Agents/metabolism , Animals , Apoptosis , Blood Cells/cytology , Blood Vessels/pathology , Brain Infarction/pathology , Brain Infarction/physiopathology , Cell Line , Cerebrovascular Circulation , Cytoprotection , Embryonic Stem Cells/cytology , Gene Expression Regulation , Humans , Infarction, Middle Cerebral Artery/chemically induced , Infarction, Middle Cerebral Artery/physiopathology , Male , Mice , Mice, Inbred C57BL , Neurons/cytology , Recovery of Function
11.
Endocrinology ; 149(8): 3764-77, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18436714

ABSTRACT

Mineralocorticoid receptors (MRs) are classically known to be expressed in the distal collecting duct of the kidney. Recently it was reported that MR is identified in the heart and vasculature. Although MR expression is also found in the brain, it is restricted to the hippocampus and cerebral cortex under normal condition, and the role played by MRs in brain remodeling after cerebral ischemia remains unclear. In the present study, we used the mouse 20-min middle cerebral artery occlusion model to examine the time course of MR expression and activity in the ischemic brain. We found that MR-positive cells remarkably increased in the ischemic striatum, in which MR expression is not observed under normal conditions, during the acute and, especially, subacute phases after stroke and that the majority of MR-expressing cells were astrocytes that migrated to the ischemic core. Treatment with the MR antagonist spironolactone markedly suppressed superoxide production within the infarct area during this period. Quantitative real-time RT-PCR revealed that spironolactone stimulated the expression of neuroprotective or angiogenic factors, such as basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), whereas immunohistochemical analysis showed astrocytes to be cells expressing bFGF and VEGF. Thereby the incidence of apoptosis was reduced. The up-regulated bFGF and VEGF expression also appeared to promote endogenous angiogenesis and blood flow within the infarct area and to increase the number of neuroblasts migrating toward the ischemic striatum. By these beneficial effects, the infarct volume was significantly reduced in spironolactone-treated mice. Spironolactone may thus provide therapeutic neuroprotective effects in the ischemic brain after stroke.


Subject(s)
Brain/physiology , Cerebral Infarction/physiopathology , Nerve Regeneration/physiology , Receptors, Mineralocorticoid/physiology , Angiogenic Proteins/metabolism , Animals , Apoptosis/drug effects , Apoptosis/physiology , Blood Pressure/drug effects , Brain/blood supply , Brain/drug effects , Brain/metabolism , Cerebral Infarction/metabolism , Drug Evaluation, Preclinical , Heart Rate/drug effects , Male , Mice , Mice, Inbred C57BL , Mineralocorticoid Receptor Antagonists , Motor Activity/drug effects , Nerve Regeneration/drug effects , Neuroprotective Agents/metabolism , Neuroprotective Agents/pharmacology , Reactive Oxygen Species/metabolism , Receptors, Mineralocorticoid/metabolism , Regional Blood Flow/drug effects , Spironolactone/pharmacology , Time Factors
12.
PLoS One ; 3(2): e1666, 2008 Feb 27.
Article in English | MEDLINE | ID: mdl-18301744

ABSTRACT

BACKGROUND: We demonstrated that mouse embryonic stem (ES) cells-derived vascular endothelial growth factor receptor-2 (VEGF-R2) positive cells could differentiate into both endothelial cells (EC) and mural cells (MC), and termed them as vascular progenitor cells (VPC). Recently, we have established a method to expand monkey and human ES cells-derived VPC with the proper differentiation stage in a large quantity. Here we investigated the therapeutic potential of human VPC-derived EC and MC for vascular regeneration. METHODS AND RESULTS: After the expansion of human VPC-derived vascular cells, we transplanted these cells to nude mice with hindlimb ischemia. The blood flow recovery and capillary density in ischemic hindlimbs were significantly improved in human VPC-derived EC-transplanted mice, compared to human peripheral and umbilical cord blood-derived endothelial progenitor cells (pEPC and uEPC) transplanted mice. The combined transplantation of human VPC-derived EC and MC synergistically improved blood flow of ischemic hindlimbs remarkably, compared to the single cell transplantations. Transplanted VPC-derived vascular cells were effectively incorporated into host circulating vessels as EC and MC to maintain long-term vascular integrity. CONCLUSIONS: Our findings suggest that the combined transplantation of human ES cells-derived EC and MC can be used as a new promising strategy for therapeutic vascular regeneration in patients with tissue ischemia.


Subject(s)
Ischemia/therapy , Neovascularization, Physiologic , Stem Cell Transplantation/methods , Animals , Cell Differentiation , Embryonic Stem Cells/cytology , Endothelial Cells/transplantation , Hindlimb , Humans , Mice , Mice, Nude , Muscle, Smooth, Vascular/cytology , Myocytes, Smooth Muscle/cytology , Regional Blood Flow , Transplantation, Heterologous
13.
Endocrinology ; 149(2): 483-91, 2008 Feb.
Article in English | MEDLINE | ID: mdl-17991722

ABSTRACT

Peripheral arterial diseases are caused by arterial sclerosis and impaired collateral vessel formation, which are exacerbated by diabetes, often leading to leg amputation. We have reported that an activation of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway accelerated vascular regeneration and blood flow recovery in murine legs, for which ischemia had been induced by a femoral arterial ligation as a model for peripheral arterial diseases. In this study, ip injection of carperitide, a human recombinant atrial natriuretic peptide, accelerated blood flow recovery with increasing capillary density in ischemic legs not only in nondiabetic mice but also in mice kept upon streptozotocin-induced hyperglycemia for 16 wk, which significantly impaired the blood flow recovery compared with nondiabetic mice. Based on these findings, we tried to apply the administration of carperitide to the treatment of peripheral arterial diseases. The study group comprised a continuous series of 13 patients with peripheral arterial diseases (Fontaine's classification I, one; II, five; III, two; and IV, five), for whom conventional therapies had not accomplished appreciable results. Carperitide was administrated continuously and intravenously for 2 wk to Fontaine's class I-III patients and for 4 weeks to class IV patients. The dose was gradually increased to the maximum, with the patient's systolic blood pressure being kept above 100 mm Hg. Carperitide administration improved the ankle-brachial pressure index, intermittent claudication, rest pain, and ulcers. In conclusion, this study showed a therapeutic potential of carperitide to treat peripheral arterial diseases refractory to conventional therapies.


Subject(s)
Atrial Natriuretic Factor/administration & dosage , Neovascularization, Physiologic/drug effects , Peripheral Vascular Diseases/drug therapy , Regional Blood Flow/drug effects , Adult , Aged , Aged, 80 and over , Animals , Arteriosclerosis Obliterans/drug therapy , Arteriosclerosis Obliterans/physiopathology , Blood Pressure/drug effects , Diabetes Mellitus, Experimental/complications , Diabetic Angiopathies/drug therapy , Diabetic Angiopathies/physiopathology , Female , Foot Ulcer/drug therapy , Foot Ulcer/physiopathology , Gangrene/drug therapy , Gangrene/physiopathology , Humans , Infusions, Intravenous , Male , Mice , Mice, Inbred C57BL , Middle Aged , Peripheral Vascular Diseases/physiopathology , Thromboangiitis Obliterans/drug therapy , Thromboangiitis Obliterans/physiopathology , Treatment Outcome
14.
Arterioscler Thromb Vasc Biol ; 27(10): 2127-34, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17872458

ABSTRACT

OBJECTIVE: We demonstrated previously that mouse embryonic stem (ES) cell-derived vascular endothelial growth factor receptor-2 (VEGF-R2)-positive cells can differentiate into both vascular endothelial cells and mural cells. This time, we investigated kinetics of differentiation of human ES cells to vascular cells and examined their potential as a source for vascular regeneration. METHODS AND RESULTS: Unlike mouse ES cells, undifferentiated human ES cells already expressed VEGF-R2, but after differentiation, a VEGF-R2-positive but tumor rejection antigen 1-60 (TRA1-60)-negative population emerged. These VEGF-R2-positive but tumor rejection antigen 1-60-negative cells were also positive for platelet-derived growth factor receptor alpha and beta chains and could be effectively differentiated into both VE-cadherin+ endothelial cell and alpha-smooth muscle actin+ mural cell. VE-cadherin+ cells, which were also CD34+ and VEGF-R2+ and thought to be endothelial cells in the early differentiation stage, could be expanded while maintaining their maturity. Their transplantation to the hindlimb ischemia model of immunodeficient mice contributed to the construction of new blood vessels and improved blood flow. CONCLUSIONS: We could identify the differentiation process from human ES cells to vascular cell components and demonstrate that expansion and transplantation of vascular cells at the appropriate differentiation stage may constitute a novel strategy for vascular regenerative medicine.


Subject(s)
Cell Differentiation , Cell Proliferation , Embryonic Stem Cells/metabolism , Endothelial Cells/metabolism , Myocytes, Smooth Muscle/metabolism , Regeneration , Actins/metabolism , Angiogenic Proteins/metabolism , Animals , Antigens, CD/metabolism , Antigens, Neoplasm/metabolism , Cadherins/metabolism , Cell Line , Cell Transformation, Neoplastic/metabolism , Disease Models, Animal , Embryonic Stem Cells/immunology , Endothelial Cells/immunology , Endothelial Cells/transplantation , Hindlimb/blood supply , Humans , Ischemia/metabolism , Ischemia/physiopathology , Ischemia/surgery , Kinetics , Mice , Mice, Inbred C57BL , Mice, Nude , Myocytes, Smooth Muscle/immunology , Myocytes, Smooth Muscle/transplantation , Neovascularization, Physiologic , Receptor, Platelet-Derived Growth Factor alpha/metabolism , Receptor, Platelet-Derived Growth Factor beta/metabolism , Regional Blood Flow , Stem Cell Transplantation , Vascular Endothelial Growth Factor Receptor-2/metabolism
15.
Endocrinology ; 147(4): 1642-53, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16384868

ABSTRACT

Adrenomedullin (AM) is a vasodilating hormone secreted mainly from vascular wall, and its expression is markedly enhanced after stroke. We have revealed that AM promotes not only vasodilation but also vascular regeneration. In this study, we focused on the roles of AM in the ischemic brain and examined its therapeutic potential. We developed novel AM-transgenic (AM-Tg) mice that overproduce AM in the liver and performed middle cerebral artery occlusion for 20 min (20m-MCAO) to examine the effects of AM on degenerative or regenerative processes in ischemic brain. The infarct area and gliosis after 20m-MCAO was reduced in AM-Tg mice in association with suppression of leukocyte infiltration, oxidative stress, and apoptosis in the ischemic core. In addition, vascular regeneration and subsequent neurogenesis were enhanced in AM-Tg mice, preceded by increase in mobilization of CD34(+) mononuclear cells, which can differentiate into endothelial cells. The vasculo-neuro-regenerative actions observed in AM-Tg mice in combination with neuroprotection resulted in improved recovery of motor function. Brain edema was also significantly reduced in AM-Tg mice via suppression of vascular permeability. In vitro, AM exerted direct antiapoptotic and neurogenic actions on neuronal cells. Exogenous administration of AM in mice after 20m-MCAO also reduced the infarct area, and promoted vascular regeneration and functional recovery. In summary, this study suggests the neuroprotective and vasculo-neuro-regenerative roles of AM and provides basis for a new strategy to rescue ischemic brain through its multiple hormonal actions.


Subject(s)
Brain Ischemia/therapy , Nerve Regeneration , Neuroprotective Agents , Peptides/physiology , Adrenomedullin , Animals , Cerebral Infarction/therapy , Corpus Striatum/blood supply , Hindlimb/blood supply , Humans , Mice , Mice, Transgenic , Neovascularization, Physiologic , Peptides/genetics , Reactive Oxygen Species
SELECTION OF CITATIONS
SEARCH DETAIL
...